Analysts Set InMode Ltd. (NASDAQ:INMD) PT at $16.80

InMode Ltd. (NASDAQ:INMD) has been assigned a consensus rating of “Hold” from the nine research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $16.80.

A number of analysts have weighed in on INMD shares. Robert W. Baird set a $17.00 target price on shares of InMode in a research report on Wednesday, February 11th. BTIG Research restated a “neutral” rating on shares of InMode in a research report on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of InMode in a research note on Thursday, January 22nd. Finally, Canaccord Genuity Group set a $15.00 price objective on shares of InMode and gave the stock a “hold” rating in a research report on Wednesday, December 17th.

Institutional Trading of InMode

A number of institutional investors have recently bought and sold shares of INMD. ARGA Investment Management LP grew its stake in InMode by 355.0% in the third quarter. ARGA Investment Management LP now owns 143,658 shares of the healthcare company’s stock valued at $2,141,000 after acquiring an additional 112,087 shares during the period. Hussman Strategic Advisors Inc. bought a new stake in shares of InMode during the third quarter valued at approximately $1,564,000. State of New Jersey Common Pension Fund D raised its position in shares of InMode by 612.1% during the third quarter. State of New Jersey Common Pension Fund D now owns 96,120 shares of the healthcare company’s stock worth $1,432,000 after purchasing an additional 82,621 shares during the period. Divisadero Street Capital Management LP acquired a new position in shares of InMode during the second quarter worth approximately $1,397,000. Finally, OMERS ADMINISTRATION Corp lifted its holdings in shares of InMode by 55.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 200,043 shares of the healthcare company’s stock worth $2,889,000 after purchasing an additional 71,231 shares in the last quarter. Institutional investors own 68.04% of the company’s stock.

InMode Trading Up 1.5%

Shares of INMD opened at $13.73 on Thursday. The stock’s 50-day moving average price is $14.24 and its two-hundred day moving average price is $14.58. InMode has a 12 month low of $12.72 and a 12 month high of $19.09. The company has a market capitalization of $869.93 million, a PE ratio of 9.53 and a beta of 2.18.

InMode (NASDAQ:INMD) last issued its quarterly earnings results on Tuesday, February 10th. The healthcare company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.04. The company had revenue of $103.85 million during the quarter, compared to analysts’ expectations of $104.64 million. InMode had a return on equity of 14.52% and a net margin of 25.33%.The business’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.42 earnings per share. Equities research analysts predict that InMode will post 1.75 EPS for the current fiscal year.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.